Market Place
Sourcing Support
Precigen To Present PRGN-2012 Plans At J.P. Morgan Conference
13 Jan 2025 //
PR NEWSWIRE
Precigen to Present at Annual J.P. Morgan Healthcare Conference
09 Jan 2025 //
PR NEWSWIRE
Precigen Reports Q3 2024 Financial Results & Business Updates
14 Nov 2024 //
PR NEWSWIRE
Precigen To Announce Q2 And H1 2024 Results On August 14
09 Aug 2024 //
PR NEWSWIRE
Precigen Announces Pricing of $30.0 Million Public Offering of Common Stock
07 Aug 2024 //
PR NEWSWIRE
Precigen to Participate in the Stifel 2023 Healthcare Conference
07 Nov 2023 //
PR NEWSWIRE
Precigen Presents Preclinical Data for the Next Generation Mesothelin UltraCAR-T
17 Apr 2023 //
PR NEWSWIRE
Precigen Reports Fourth Quarter and Full Year 2022 Financial Results
06 Mar 2023 //
PR NEWSWIRE
Precigen Announces PI Dose Escalation Data for Autologous PRGN-3006 UltraCAR-T
12 Dec 2022 //
PRNEWSWIRE
Precigen Names Rutul R. Shah Chief Operating Officer
21 Sep 2022 //
PRNEWSWIRE
Precigen Reports Second Quarter and First Half 2022 Financial Results
08 Aug 2022 //
PRNEWSWIRE
Precigen Receives FTD for PRGN-3006 UltraCAR-T in r/r AML
04 Apr 2022 //
PRNEWSWIRE
Precigen Provides Pipeline and Corporate Updates at JPM 2022
12 Jan 2022 //
PRNEWSWIRE
Precigen Achieves Significant Clinical Progress for UltraCAR-T®
04 Nov 2021 //
PRNEWSWIRE
Precigen Achieves Significant Clinical Progress for UltraCAR-T
04 Nov 2021 //
FIRSTWORDPHARMA
Precigen to Host R&D Update Virtual Event to Share Clinical Developments
27 Oct 2021 //
PRNEWSWIRE
Precigen to Announce Second Quarter and First Half 2021 Financial Results
02 Aug 2021 //
PRNEWSWIRE
Precigen Announces First Patient Dosed for PRGN-2012 AdenoVerse™ Immunotherapy
23 Mar 2021 //
PRNEWSWIRE
US FDA grants orphan drug status to Precigen’s PRGN-2012 AdenoVerse
19 Mar 2021 //
PHARMABIZ
Precigen Announces Pricing of $112.5 Million Public Offering of Common Stock
22 Jan 2021 //
PRNEWSWIRE
Precigen Provides Pipeline Updates at the 39th Annual J.P. Morgan
13 Jan 2021 //
PRNEWSWIRE
Precigen Announces Clearance of IND to Initiate Ph I Study of PRGN-2012
05 Jan 2021 //
PRNEWSWIRE
Precigen Provides Latest Clinical Developments at Virtual R&D Update Event
15 Dec 2020 //
PRNEWSWIRE
Precigen Presents New Data Supporting the Safety, of PRGN-3006
07 Dec 2020 //
PRNEWSWIRE
Precigen Announces Dosing of First Patients with UltraCAR-T® Cells Manufactured
16 Nov 2020 //
PRNEWSWIRE
Stock Alert: Precigen Climbs 20% As Merck Increases Stake In The Co.
09 Oct 2020 //
NASDAQ
Precigen Announces First Patient Dosed in Phase I/II Study PRGN-2009
17 Aug 2020 //
PRNEWSWIRE
Preclinical Data for PRGN-3005 UltraCAR-T® Demonstrate Superior Expansion
22 Jun 2020 //
PRNEWSWIRE
Precigen to Present Preclinical Data for PRGN-3005 UltraCAR-T™
15 May 2020 //
PRNEWSWIRE
Precigen Announces of IND to Initiate Ph I/II Study for First-in-Class PRGN-2009
20 Apr 2020 //
PR NEWSWIRE
New year, new name, new CEO for synthetic biology co. Intrexon
04 Jan 2020 //
FIERCE BIOTECH
Intrexon To Achieve $175M Cash Goal, Appoints Helen Sabzevari, PhD, As CEO
02 Jan 2020 //
PR NEWSWIRE
Intrexon sells AquaBounty stake to CEO-affiliated aquaculture business
31 Oct 2019 //
SEEKINGAPHA
Precigen Announces First Patient Dosed in Phase 1/1b of PRGN-3006 UltraCAR-T
26 Jun 2019 //
BIOSPACE
Intrexon and Surterra Wellness to Collaborate on Botticelli™
04 Mar 2019 //
BIOSPACE
Ex-Eli Lilly CFO becomes president of PBM business
23 Mar 2018 //
ENDPTS
Where Billionaire-Led Intrexon (XON) Could Be in 10 Years
19 Apr 2017 //
BIOSPACE
Intrexon to buy floundering GenVec for gene delivery tech
26 Jan 2017 //
FIERCE BIOTECH
Former Novartis exec David Epstein becomes Flagship VC partner
04 Jan 2017 //
FIERCE BIOTECH
